|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211914-51-1
|
|
gptkbp:contraindication
|
active pathological bleeding
mechanical prosthetic heart valve
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:hasInChIKey
|
PTZSUBHDPIDFOT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
gptkbp:hasSMILES
|
CCOC(=O)C1=C(C(=O)N(C2=CC=CC=C12)C3=NC4=CC=CC=C4N3C)N5CCN(CC5)C(=O)N
|
|
gptkbp:hasUNII
|
2XTZ996338
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB01270
|
|
gptkbp:indication
|
treatment and prevention of deep vein thrombosis
treatment and prevention of pulmonary embolism
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:mechanismOfAction
|
direct thrombin inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
627.74
|
|
gptkbp:name
|
gptkb:Dabigatran
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:PubChem_CID
|
gptkb:DB01270
gptkb:CHEMBL502
148124
D08167
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:synonym
|
gptkb:Dabigatran_etexilate
|
|
gptkbp:bfsParent
|
gptkb:ranibizumab
|
|
gptkbp:bfsLayer
|
6
|